Less than a week after Frequency Therapeutics said it had cut a licensing deal with a big Japanese drug maker, the Woburn biotech announced Tuesday that it has raised $62 million in venture capital from investors enticed by the firm’s efforts to combat hearing loss.
The fundraising round, which is Frequency’s third, means it has collected a total of $147 million from investors. And that’s separate from the $80 million that the four-year-old company will receive up front in the deal it just signed with Tokyo-based Astellas Pharma (ALPMY) to help develop and market Frequency’s experimental drug outside the United States.
